These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 20508021

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Targeting drug companies' bottom line.
    Prescrire Int; 2011 Jan; 20(112):25. PubMed ID: 21462792
    [No Abstract] [Full Text] [Related]

  • 4. Bitter pills for drug companies.
    Newman M.
    BMJ; 2010 Sep 17; 341():c5095. PubMed ID: 20851842
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pfizer versus Kaiser: insurers want their day in court.
    Silverman E.
    BMJ; 2013 Jun 12; 346():f3738. PubMed ID: 23760967
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pfizer to pay $430 million over promoting drug to doctors.
    Harris G.
    N Y Times Web; 2004 May 14; ():C6. PubMed ID: 15290803
    [No Abstract] [Full Text] [Related]

  • 10. Malfeasance on an industrial scale.
    Prescrire Int; 2013 Feb 14; 22(135):32. PubMed ID: 23444493
    [No Abstract] [Full Text] [Related]

  • 11. Off-label marketing: free speech or illegal promotion?
    Silverman E.
    BMJ; 2013 Jan 22; 346():f320. PubMed ID: 23341546
    [No Abstract] [Full Text] [Related]

  • 12. GlaxoSmithKline is fined record $3bn in US.
    Roehr B.
    BMJ; 2012 Jul 03; 345():e4568. PubMed ID: 22761252
    [No Abstract] [Full Text] [Related]

  • 13. Johnson & Johnson pays $181m for misleading marketing of risperidone.
    Tanne JH.
    BMJ; 2012 Sep 03; 345():e5916. PubMed ID: 22945959
    [No Abstract] [Full Text] [Related]

  • 14. Pharmaceuticals and medical devices: FDA oversight.
    Health Policy Tracking Service, a service of Thomson Reuters Accelus, Berry MD.
    Issue Brief Health Policy Track Serv; 2012 Jan 03; ():1-86. PubMed ID: 22403845
    [No Abstract] [Full Text] [Related]

  • 15. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
    Roehr B.
    BMJ; 2012 Dec 06; 345():e8324. PubMed ID: 23220261
    [No Abstract] [Full Text] [Related]

  • 16. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
    Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J.
    Health Aff (Millwood); 2011 Dec 06; 30(12):2318-27. PubMed ID: 22147859
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK.
    Food Drug Law J; 2006 Dec 06; 61(3):577-83. PubMed ID: 16989041
    [No Abstract] [Full Text] [Related]

  • 19. Court rules that FDA cannot restrict off-label marketing.
    Roehr B.
    BMJ; 2015 Aug 11; 351():h4367. PubMed ID: 26265632
    [No Abstract] [Full Text] [Related]

  • 20. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
    Vilhelmsson A, Davis C, Mulinari S.
    PLoS Med; 2016 Jan 11; 13(1):e1001945. PubMed ID: 26812151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.